# The GH-Axis FAQ > Growth Hormone Axis Research Peptides FAQ | The Peptide Brand — Direct answers about Growth Hormone Axis research peptides, including sermorelin, tesamorelin, CJC-1295, and ipamorelin, with citations and caveats. **READER QUESTIONS / EVIDENCE ANSWERS** Concise answers that keep receptor, population, endpoint, and uncertainty attached. ## What is sermorelin? Sermorelin is a synthetic version of the first 29 amino acids of human growth hormone-releasing hormone. It activates GHRH receptors on pituitary cells, prompting the body’s own growth-hormone release. Human studies document endocrine response in healthy men, children with GH deficiency, and a small older-men group [5][6][7]. Those findings do not establish sermorelin as an anti-aging treatment. ## What does sermorelin do to the body? Its direct documented action is to stimulate pituitary GH release, which can raise downstream IGF-1. Because that signal passes through the pituitary, feedback controls remain involved. A short study in older men found higher daily GH and IGF-1 measures without a fasting-glucose change during the study window [7]. Longer-term wellness outcomes and safety are not established. ## Does sermorelin work? It depends on the endpoint. Sermorelin clearly stimulated GH release in human pharmacology work [6], supported growth in children with GH deficiency [5], and raised GH-axis measures in a small older-men study [7]. Evidence does not establish that it prevents or reverses aging; an editorial concluded that secretagogues were not ready for that use [3]. ## How quickly were sermorelin effects measured in studies? Timing varies by endpoint. In a healthy-volunteer pharmacology study, GH remained elevated for roughly three hours after intravenous GHRH(1-29) [6]. An older-men study evaluated repeated exposure over 14 days [7], while pediatric growth was assessed across the first treatment year [5]. Those observation windows describe research measurements, not a recommended schedule or expected personal result. ## What is tesamorelin? Tesamorelin is a stabilized 44-amino-acid GHRH analogue. It is an approved prescription medicine for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [9]. Its evidence base includes randomized trials and a pooled analysis in that defined population [8][10][12]. Approval for one indication does not establish general weight-loss or anti-aging use. ## How does tesamorelin work? Tesamorelin activates pituitary GHRH receptors, increasing pulsatile endogenous GH release and downstream IGF-1. In a short study of healthy men, overnight GH and IGF-1 rose while fasting glucose and measured insulin-stimulated glucose uptake did not significantly change [11]. The mechanism helps explain fat-compartment research but does not guarantee the same outcome in unstudied populations. ## Does tesamorelin reduce belly fat? Trials support a reduction in visceral abdominal fat in adults with HIV-associated lipodystrophy. A pooled analysis of five randomized studies and individual clinical trials reported significant visceral-fat reductions [8][10][12]. The evidence is population-specific, and one longer program found reaccumulation after discontinuation [12]. It should not be reframed as a general abdominal-weight-loss promise. ## What is CJC-1295? CJC-1295 is a modified GHRH analogue. The long-acting DAC version binds albumin, extending exposure, while a no-DAC form is shorter acting. Human studies measured sustained GH and IGF-1 elevation and preserved GH pulses [15][16]. The record is early pharmacology, not proof of anti-aging, muscle, recovery, or fat-loss outcomes. ## Is CJC-1295 proven safe? No long-term human safety database in the composed evidence supports that conclusion. Early healthy-adult studies measured multi-day GH and IGF-1 changes [15][16], but they were not large or long enough to resolve chronic metabolic, fluid-balance, growth-signaling, or cardiovascular questions. The compound has no approved human indication, and DAC/no-DAC naming confusion further complicates interpretation. ## Is there an established CJC-1295 human regimen? This digest does not provide human dosing. Published early studies administered defined amounts under research protocols to characterize pharmacology [15][16]; those designs are not treatment recommendations. CJC-1295 has no approved human indication, and informal schedules are not substitutes for controlled evidence—especially when the DAC and no-DAC forms have very different persistence. ## What is ipamorelin? Ipamorelin is a five-residue growth-hormone secretagogue that activates the ghrelin receptor, GHS-R1a. Human pharmacology work found a short terminal half-life and a discrete GH pulse [20]. It differs mechanistically from GHRH analogues, and it is not an approved medicine. Human outcomes evidence is sparse. ## What are the main evidence gaps and risks for ipamorelin? The main gap is long-term human data. A postoperative Phase 2 study missed its primary endpoint [19], while several findings come from animals [17][21]. A different GHS-R1a agonist produced myocardial injury signals in a repeated-dose rat study; that is a class caution, not an ipamorelin-specific finding [18]. Appetite, fluid balance, glucose regulation, product identity, and chronic GH-axis exposure remain unresolved concerns. --- The Peptide Brand is an independent field guide to the aging GH axis—curious about every signal, exacting about every caveat, and never a clinic, vendor, or prescription.